Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.84 |
| ▸ | EP300 | Q09472 | 3/20 | 0.80 |
| ▸ | CHAT | P28329 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.80 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558687 | 1.00 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL380100 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL31475488 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL380634 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL1332729 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL25273107 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL11026148 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2510648 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2317294 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2506879 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388874-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | GENOMATICA INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250290048-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | CREO INGREDIENTS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250171813-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | CREO INGREDIENTS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12123045-B2 | Genetically modified cells that produce C6-C10 fatty acid derivatives | CARGILL, INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4396335-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | Genomatica, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240141397-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS | AGAIN BIO APS (DK) | 2024-05-02 | — | — | US | disclosed |
| US-20230332193-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | CREO INGREDIENTS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11781120-B2 | Biosynthesis of polyketides | Gonzalez, Ramon (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4208540-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | Genomatica, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023034862-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | GENOMATICA, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7527963-B2 | Acetyl-CoA acyltransferase gene disrupted bacterium for producing polyhydroxyalkanoate and method for producing polyhydroxyalkanoate using the same | CANON KABUSHIKI KAISHA (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060172399-A1 | Acetyl-CoA acyltransferase gene disrupted bacterium for producing polyhydroxyalkanoate and method for producing polyhydroxyalkanoate using the same | CANON KABUSHIKI KAISHA (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1161539-B1 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES IN RECOMBINANT ORGANISMS | UNIV LAVAL (CA) | 2005-07-27 | — | — | EP | disclosed |
| US-6492134-B1 | SELECTING A HOST FOR EXPRESSION OF GENES ENCODING ENZYMES REQUIRED FOR SYNTHESIS OF A POLYHYDROXYALKANOATE; INTRODUCING INTO SAID HOST STRUCTURAL GENES ENCODING A THIOESTERASE, AN ACYL-COA SYNTHETASE, A THIOLASE, A YEAST (R)-3-HYDROXYACYL-COA | UNIVERSITé LAVAL (CA) | 2002-12-10 | — | — | US | disclosed |
| EP-1161539-A1 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES IN RECOMBINANT ORGANISMS | UNIVERSITE LAVAL (CA) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055328-A1 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES IN RECOMBINANT ORGANISMS | UNIVERSITE LAVAL (CA) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388874-A1 | FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY | BLVRB, SQOR, CYP2F1 | NAA50 546/4885EP300 4408/4885CHAT 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.